Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease.

ABSTRACT:

Background

Treatment is indicated in dogs with preclinical degenerative mitral valve disease (DMVD) and cardiomegaly (stage B2). This is best diagnosed using echocardiography; however, relying upon this limits access to accurate diagnosis.

Objectives

To evaluate whether cardiac biomarker concentrations can be used alongside other clinical data to identify stage B2 dogs.

Animals

Client-owned dogs (n = 1887) with preclinical DMVD prospectively sampled in Germany, the United Kingdom, and the United States.

Methods

Dogs that met inclusion criteria and were not receiving pimobendan (n = 1245) were used for model development. Explanatory (multivariable logistic regression) and predictive models were developed using clinical observations, biochemistry, and cardiac bio

SUBMITTER: Wilshaw J 

PROVIDER: S-EPMC7995403 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature